Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the …

Advanced stage hepatocellular carcinoma (HCC) is a category of disease defined by
radiological, clinical and hepatic function parameters, comprehending a wide range of …

The present study aimed to examine the impact of sarcopenia, defined as low muscle mass
on computed tomography (CT), prior to sorafenib therapy on the clinical outcomes of …

Purpose To assess the safety of locoregional treatment (LRT) combined with nivolumab for
intermediate and advanced hepatocellular carcinoma (HCC). Materials and Methods A …

Abstract Background and Aim The Albumin‐Bilirubin (ALBI) grade is a new index to assess
objectively liver function and prognosis in patients with hepatocellular carcinoma (HCC) …

Background There is no consensus on the effect of sorafenib dosing on efficacy and toxicity
in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically …

Background The hepatic resection for hepatocellular carcinoma (HCC) with portal vein
tumor thrombus (PVTT) which is not uncommon at clinic continues to be debated. Our study …

Sorafenib is not recommended for advanced hepatocellular carcinoma (HCC) patients with
Vp4 (portal invasion at the main trunk) by the Japan Society of Hepatology (JSH) due to a …

Background Sorafenib was approved for treatment of unresectable hepatocellular
carcinoma (HCC) in Japan in 2009. A prospective postmarketing all-patient surveillance …

For hepatocellular carcinoma (HCC) patients with macrovascular invasion (MaVI),
hepatectomy and transcatheter arterial chemoembolization (TACE) remain the main …